After A Tough 2012, Lundbeck Says It Is Benefiting From A Portfolio Revamp
This article was originally published in The Pink Sheet Daily
Executive Summary
Following a tough 2012 that saw the end of exclusivity for key drug Lexapro and infrastructure cutbacks in Europe due to pricing headwinds, mid-sized EU specialty pharma Lundbeck could see a return to growth in 2013. The company is banking on regulatory approval of three drugs, and preparing to release first-time Phase III data from a fourth.